Challenges in international investigator-led rare disease clinical trials and the case for optimism in inclusion body myositis
Instrumental to the progress of the trial has been the collaboration between site teams, patient partnership and adaptability.
Authors
- Kelly Beer (ORCID: https://orcid.org/0000-0003-0875-781X)
- Olivier Benvéniste (ORCID: https://orcid.org/0000-0002-1167-5797)
- Mazen M. Dimachkie (ORCID: https://orcid.org/0000-0002-7148-989X)
- Merrilee Needham (ORCID: https://orcid.org/0000-0001-6591-1444)
- Umesh A. Badrising (ORCID: https://orcid.org/0000-0003-0146-2664)
- Aneesya Panicker (ORCID: https://orcid.org/0000-0001-7902-3472)
- Althea Doverty
- Andrew Heim (ORCID: https://orcid.org/0009-0003-0845-6635)
Institutions
- Leiden University Medical Center (NL)
- Sorbonne Université (FR)
- Pitié-Salpêtrière Hospital (FR)
- University of Kansas Medical Center (US)
- Perron Institute for Neurological and Translational Science (AU)
Publication Details
- Journal
- Clinical and Experimental Rheumatology
- Published
- 2025-02-26
- DOI
- https://doi.org/10.55563/clinexprheumatol/dyjcsn
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 0.00